B*44 restricted peptides for use in immunotherapy against cancers and related methods
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
1. A method of treating a patient who has cancer, comprising administering to said patient a population of activated T cells that kill cancer cells that present a peptide consisting of the amino acid sequence of SEQ ID NO: 364,
wherein the activated T cells are cytotoxic T cells produced by in vitro contacting T cells with an antigen presenting cell that expresses the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell,
wherein said cancer is selected from breast cancer, cholangiocellular carcinoma, chronic lymphocytic leukemia, colorectal cancer, gastric cancer, hepatocellular carcinoma, head and neck squamous cell carcinoma, non-Hodgkin lymphoma, non-small cell lung cancer, ovarian cancer, esophageal cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, urinary bladder carcinoma, and uterine and endometrial cancer.
2. The method of claim 1 , wherein the T cells are autologous to the patient.
3. The method of claim 1 , further comprising administering to said patient an adjuvant selected from anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I:C), RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.
4. The method of claim 1 , wherein the cancer is breast cancer.
5. The method of claim 1 , wherein the cancer is cholangiocellular carcinoma.
6. The method of claim 1 , wherein the cancer is chronic lymphocytic leukemia.
7. The method of claim 1 , wherein the cancer is colorectal cancer.
8. The method of claim 1 , wherein the cancer is gastric cancer.
9. The method of claim 1 , wherein the cancer is hepatocellular carcinoma.
10. The method of claim 1 , wherein the cancer is head and neck squamous cell carcinoma.
11. The method of claim 1 , wherein the cancer is non-Hodgkin lymphoma.
12. The method of claim 1 , wherein the cancer is non-small cell lung cancer.
13. The method of claim 1 , wherein the cancer is ovarian cancer.
14. The method of claim 1 , wherein the cancer is esophageal cancer.
15. The method of claim 1 , wherein the cancer is pancreatic cancer.
16. The method of claim 1 , wherein the cancer is prostate cancer.
17. The method of claim 1 , wherein the cancer is renal cell carcinoma.
18. The method of claim 1 , wherein the cancer is urinary bladder carcinoma.
19. The method of claim 1 , wherein the cancer is uterine and endometrial cancer.
20. The method of claim 3 , wherein the adjuvant is IL-7.